Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report by State

Non-Hodgkin Lymphoma (Late Stage^), 2016-2020

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by CI*Rank

Explanation of Column Headers

Objective - The objective of *** is from the Healthy People 2020 project done by the Centers for Disease Control and Prevention.

Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Percent of Cases with Late Stage - This is the number of late stages cases compared to the number of cases for all stages.


Other Notes


Line by Line Interpretation of the Report


US (SEER+NPCR)1


Iowa3


Wisconsin6


Maine6


Minnesota6


South Dakota6


West Virginia6


Kentucky3


Pennsylvania6


Ohio6


Idaho3


Connecticut3


New Jersey3


New York3


New Hampshire6


Nebraska6


Missouri6


Kansas6


Massachusetts3


Michigan6


Illinois3


North Dakota6


Maryland6


Utah3


Vermont6


Montana6


Louisiana3


Washington5


Rhode Island6


North Carolina6


California3


Oregon6


Delaware6


Georgia3


Colorado6


Florida6


Arkansas6


Alaska6


Oklahoma6


Tennessee6


Virginia6


Texas3


Mississippi6


South Carolina6


Wyoming6


Alabama6


Hawaii3


Arizona6


District of Columbia6


New Mexico3


Puerto Rico6


Indiana6 Nevada6

Notes:
Created by statecancerprofiles.cancer.gov on 03/02/2024 10:03 pm.

State Cancer Registries may provide more current or more local data.

Data cannot be shown for the following areas. For more information on what areas are suppressed or not available, please refer to the table.
Indiana, Nevada

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.

Source: SEER and NPCR data. For more specific information please see the table.
Data not available for this combination of geography, cancer site, age, and race/ethnicity.

Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.